Related Experiment Video
Updated: May 1, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Virus inactivation during coagulation with aluminum coagulants
Taku Matsushita1, Nobutaka Shirasaki, Yoshihiko Matsui
1Graduate School of Engineering, Hokkaido University, N13W8, Sapporo 060-8628, Japan. taku-m@eng.hokudai.ac.jp
Abstract:
We used the bacteriophages Qβ and MS2 to determine whether viruses are inactivated by aluminum coagulants during the coagulation process. We performed batch coagulation and filtration experiments with virus-containing solutions. After filtering the supernatant of the coagulated solution through a membrane with a pore size of 50 nm, we measured the virus concentration by both the plaque forming unit (PFU) and polymerase chain reaction (PCR) methods. The virus concentration determined by the PFU method, which determines the infectious virus concentration, was always lower than that determined by the PCR-based method, which determines total virus concentration, regardless of infectivity. This discrepancy can be explained by the formation of aggregates consisting of several virus particles or by the inactivation of viruses in the coagulation process. The former possibility can be discounted because (i) aggregates of several virus particles would not pass through the 50-nm pores of the filtration membrane, and (ii) our particle size measurements revealed that the virus particles in the membrane filtrate were monodispersed. These observations clearly showed that non-infectious Qβ particles were present in the membrane filtrate after the coagulation process with aluminum coagulants. We subsequently revealed that the viruses lost their infectivity after being mixed with hydrolyzing aluminum species during the coagulation process.
Related Concept Videos
Colloidal precipitates
Precipitation and Co-precipitation
Coagulation
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

